Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXR NASDAQ:NEUP NASDAQ:PRPH NYSEAMERICAN:TOVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$1.23-4.7%$1.38$0.65▼$23.22$13.08M1.19560,047 shs251,048 shsNEUPNeuphoria Therapeutics$7.43-4.1%$7.35$2.12▼$12.55$13.97M0.5339,499 shs22,213 shsPRPHProPhase Labs$0.31-4.3%$0.37$0.22▼$3.00$12.97M-0.481.01 million shs371,601 shsTOVXTheriva Biologics$0.37-4.9%$0.46$0.37▼$7.15$3.36M0.77373,023 shs200,677 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals0.00%-4.65%-24.54%+64.00%-94.57%NEUPNeuphoria Therapeutics0.00%-7.70%-2.24%+48.30%+742,999,900.00%PRPHProPhase Labs0.00%-4.26%-27.36%+3.04%-87.90%TOVXTheriva Biologics0.00%-14.34%-21.08%-29.99%-93.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXRCitius Pharmaceuticals1.899 of 5 stars3.32.00.00.01.10.81.3NEUPNeuphoria Therapeutics1.1326 of 5 stars3.50.00.00.00.00.00.6PRPHProPhase Labs0.7303 of 5 stars0.05.00.00.01.30.00.6TOVXTheriva Biologics1.1837 of 5 stars3.03.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.50Moderate Buy$53.004,208.94% UpsideNEUPNeuphoria Therapeutics 3.00Buy$21.00182.64% UpsidePRPHProPhase Labs 0.00N/AN/AN/ATOVXTheriva Biologics 2.00Hold$6.001,517.25% UpsideCurrent Analyst Ratings BreakdownLatest TOVX, NEUP, PRPH, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.006/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/ANEUPNeuphoria Therapeutics$10K1,396.84N/AN/A$15.85 per share0.47PRPHProPhase Labs$6.77M1.92N/AN/A$0.25 per share1.25TOVXTheriva BiologicsN/AN/AN/AN/A$6.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$39.14MN/A0.000.98N/AN/A-58.63%-37.67%8/11/2025 (Estimated)NEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)TOVXTheriva Biologics-$25.65M-$33.06N/A∞N/AN/A-97.50%-55.31%N/ALatest TOVX, NEUP, PRPH, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PRPHProPhase Labs-$0.15N/AN/AN/A$3.55 millionN/A8/11/2025Q3 2025CTXRCitius Pharmaceuticals-$0.76N/AN/AN/A$1.92 millionN/A5/20/2025Q3 2025NEUPNeuphoria Therapeutics-$0.47$6.55+$7.02$6.55N/A$15.00 million5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ATOVXTheriva BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.370.06NEUPNeuphoria TherapeuticsN/A11.0111.01PRPHProPhase Labs0.301.030.98TOVXTheriva Biologics0.101.531.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%NEUPNeuphoria Therapeutics15.90%PRPHProPhase Labs9.45%TOVXTheriva Biologics6.17%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals10.70%NEUPNeuphoria Therapeutics0.69%PRPHProPhase Labs9.60%TOVXTheriva Biologics1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/APRPHProPhase Labs13041.54 million37.55 millionOptionableTOVXTheriva Biologics209.06 million8.93 millionNot OptionableTOVX, NEUP, PRPH, and CTXR HeadlinesRecent News About These CompaniesTheriva Biologics Sets 2025 Shareholder Meeting DateJune 25, 2025 | tipranks.comTheriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review ...May 29, 2025 | finanznachrichten.deTheriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the ...May 29, 2025 | morningstar.comMTheriva Biologics, Inc.: Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial ResultsMay 14, 2025 | finanznachrichten.deTheriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial ResultsMay 14, 2025 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Announces Closing of $7.5 Million Public OfferingMay 9, 2025 | finanznachrichten.deTheriva Biologics Announces Pricing of Public Offering for $7.5 Million to Support Cancer Therapeutics DevelopmentMay 9, 2025 | nasdaq.comTheriva Biologics Announces Closing of $7.5 Million Public OfferingMay 8, 2025 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Announces Pricing of $7.5 Million Public OfferingMay 7, 2025 | finanznachrichten.deTheriva’s oncolytic virus succeeds in pancreatic cancer study, but stock fallsMay 7, 2025 | endpts.comETheriva Biologics Announces Pricing of $7.5 Million Public OfferingMay 7, 2025 | globenewswire.comTheriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsApril 10, 2025 | globenewswire.comTheriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025April 2, 2025 | nasdaq.comTheriva Biologics says IDMC considers VCN-01 to be well toleratedApril 2, 2025 | markets.businessinsider.comTheriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New OrleansMarch 21, 2025 | nasdaq.comTheriva™ Biologics to Present at the 2025 NeauxCancer ConferenceMarch 19, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Myomo (MYO) and Theriva Biologics (TOVX)March 12, 2025 | markets.businessinsider.comTheriva Biologics Reports 2024 Financial Results and ProgressMarch 7, 2025 | tipranks.comTheriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial ResultsMarch 6, 2025 | globenewswire.comTheriva™ Biologics to Participate in the Q1 Investor Summit VirtualMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOVX, NEUP, PRPH, and CTXR Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$1.23 -0.06 (-4.65%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.25 +0.02 (+1.22%) As of 08/8/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Neuphoria Therapeutics NASDAQ:NEUP$7.43 -0.32 (-4.13%) As of 08/8/2025 04:00 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.ProPhase Labs NASDAQ:PRPH$0.31 -0.01 (-4.26%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$0.33 +0.02 (+6.34%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Theriva Biologics NYSEAMERICAN:TOVX$0.37 -0.02 (-4.87%) Closing price 08/8/2025 04:10 PM EasternExtended Trading$0.37 0.00 (-0.27%) As of 08/8/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
